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Abstract: Epigenetic modifications include DNA methylation and covalent modification of histones. These alterations are
reversible but very stable and exert a significant impact on the regulation of gene expression. Changes in methylation of
promoter or first exon may mimic the effect of mutations of various tumor suppressor genes (TSGs) or protooncogenes.
Carcinogenesis can also result from aberrations in genomic DNA methylation that include hypermethylation and hypomethylation
of promoter or first exon of cancer-related genes. Hypermethylation of promoter of various TSGs causes their transcriptional
silencing. However, hypomethylation of regulatory DNA sequences activates transcription of protooncogenes, retrotransposons, as
well as genes encoding proteins involved in genomic instability and malignant cell metastasis. The methylation of genomic DNA
in malignant cells is catalyzed by DNA methyltransferases DNMT1 and DNMT3B, revealing significantly elevated expression in
different types of cancers. The reversibility of hypermethylation can be used as target of therapeutic treatment in cancer. DNMT1
and DNMT3B inhibitors including 5-Aza-2’-deoxycytidine and antisense oligonucleotides have been applied in clinical trials of
such treatment. Identification of aberrations of DNA methylation in cancer cells is a new field of investigation in carcinogenesis.
We believe that epigenetic cancer diagnostic and therapy will be achieved in the next decades.
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Introduction
Development of cancer may result from inherited muta-
tions in the germ line or from changes in DNA sequences
arising in somatic tissues during life. These mutations
may abnormally enhance the function of protoon-
cogenes, or erase effects of the tumor suppressor gene
(TSG) products [47, 86]. Carcinogenesis can also result
from aberrations of genomic DNA methylation that
include hypermethylation and hypomethylation of pro-
moter or first exon of cancer-related genes. Changes in
methylation of promoter or first exon may mimic the
effect of mutations of TSGs or protooncogenes. Hyper-
methylation of promoter and first exon of various TSGs
causes their transcriptional silencing. However, hypo-
methylation of regulatory DNA sequences activates
transcription of protooncogenes, retrotransposons, as
well as genes encoding proteins involved in genomic
instability and malignant cell metastasis. TSG products
are normally involved in holding cellular growth at the
checkpoint and inhibit expression of the tumorigenic
phenotype [79, 82]. Inactivation or loss of TSG products
removes a barrier of normal proliferation, which may
result in malignant transformation. Oncogenes are
derived from normal protooncogenes, that play key roles
in cellular processes such as regulation of gene express-
ion or cell growth and cytoplasmic signal transduction.
Mutation of protooncogene results in formation of on-
cogene and its protein product exhibits sustained activity
responsible for malignant transformation of cells [71].
5-Methylcytosine (m5C) was first found in DNA of
higher eukaryotes by Hotchkiss in 1948. Methylation of
cytosine within cytosine-guanine dinucleotide (CpG) se-
quences in the 5’-position of the pyrimidine ring is used
for epigenetic modulation of chromatin structure and regu-
lation of gene expression in vertebrates. The presence of
m5CpG in genomic DNA is associated with condensation
of chromatin, stabilization of chromosomes, transcrip-
tional silencing of X chromosome, genomic imprinting and
tissue-specific silencing of gene expression. This epi-
genetic regulation also coordinates gene expression during
cell differentiation in mammalian embryogenesis [8, 88].
The methylation of mammalian genomic DNA is cata-
lyzed by DNA methyltransferases (DNMTs) that can be
divided into maintenance and de novo DNMTs. Express-
ion of these DNMTs is significantly elevated in cancers of
breast, colon, endometrium, prostate, stomach and in
uterine leiomyomata [40, 70, 100, 103, 121, 124].
Two types of DNMT inhibitors are now in clinical
trials of cancer treatment: nucleoside analog 5-Aza-2’-
deoxycytidine (5-aza-CdR) which is incorporated into
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DNA and inactivates DNMTs [125] and antisense oli-
gonucleotide which induces degradation of DNMT1
mRNA and inhibits enzyme biosynthesis [69].
Epigenetic modification
Epigenetic modification is defined as a heritable, revers-
ible change in gene expression that does not result from
DNA sequence alterations [11, 27, 77, 114, 125].
Epigenetic modifications include DNA methylation
and covalent modification of histones. These alterations
are reversible but very stable and exert a significant
impact on the regulation of gene expression and the
development of vertebrates [99]. In mammals, m5C is
primarily located in CpG islands of promoter and first
exon sequences, which exhibit highly conservative
DNA methylation pattern. CpG islands are 0.5 to several
kb DNA sequences that contain 60-70% of CpG dinu-
cleotides [12, 25, 77, 92]. Human genome contains
29000 CpG islands [24] and approximately half of genes
possess these islands [5, 27]. Completely methylated
CpG islands are found only in promoters of untran-
scribed autosomal genes and transcriptionally silenced
genes of inactive female X-chromosomes [12].
The N-terminal tails of histones are epigenetically
modified by histone acetyltransferases (HATs), histone
deacetylases (HDACs) and histone methyltransferases
(HMTs). These enzymes acetylate, deacetylate or
methylate ε and guanidine amine groups of histone Lys
(K) or Arg (R) amino acid residues, respectively [126].
The multiple covalent modifications on the same histone
tail create specific epigenetic patterns that switch genes
between their active and transcriptionally inactive stages
and correlate with distinct biological events [76, 126].
HDACs, HATs, HMTs and DNMTs play crucial roles
in the epigenetic regulation of gene expression involved
in carcinogenesis [36, 110]. Alteration of transcription-
ally active euchromatin to transcriptionally inactive
heterochromatin requires histone remodeling enzymes
HDACs, HATs, HMTs (Suv39h1/2, G9a, EZH2) and
ATP-dependent chromatin remodeling enzymes (e.g.
hSNF2H) [36]. Methylation level of K4, K9 and K27
amino acid residues of H3 histone corresponds to eu-
chromatin, facultative heterochromatin and constitutive
heterochromatin structures, respectively (Fig. 1) [36].
HMT (Suv39h1) attaches methyl group to K9 amino acid
residues of H3 histone that further recruits heterochromatin
protein 1 (HP1). Interactions of HP1 with methylated K9
of H3 histone and transcriptional complex components are
essential for formation and maintenance of heterochro-
matin structure [10, 17, 87, 105, 118].
Mammalian DNMTs interact with HP1, HDAC1,
HDAC2, and HMTs, moreover DNMT3B additionally
recruits the ATP-dependent chromatin remodeling
enzyme hSHF2H involved in heterochromatin structure
formation [36]. The covalent modification of histones
associated with transcriptional silencing of TSGs and
other genes is initiated by DNA methyltransferases.
DNA methyltransferases (DNMTs)
The mammalian DNMTs family encompasses DNMT1,
DNMT2, DNMT3A and DNMT3B. This family is
divided into maintenance and de novo methyltransfer-
Fig. 1. Methylation level of K4, K9
and K27 amino acid residues of H3
histone corresponds to euchro-
matin, facultative and constitutive
heterochromatin structures, respec-
tively [38, 126].
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ases. Maintenance DNMT1 binds methyl groups to the
hemimethylated DNA during replication, whereas de
novo DNMT3A and DNMT3B add methyl groups to
CpG dinucleotides of unmethylated DNA (Fig. 2). Ho-
mozygous loss of DNMT1, DNMT3A and DNMT3B is
lethal in mice [15], that suggests the crucial role of these
enzymes in the regulation of embryogenesis. DNMT1,
DNMT3A and DNMT3B are required for formation of
the established pattern of methylation in promoters and
first exons of human genomic DNA [27]. In somatic
cells, the pattern of DNA methylation is highly conser-
vative and during cell division is kept by maintenance
DNA methyltransferase (DNMT1) [27, 77, 92]. This
enzyme is a component of DNA replication complex
[111] and maintains the DNA methylation via addition
of a methyl group to the 5-position of the cytosine ring
within the CpG dinucleotides of newly synthesized
DNA strand (Figures 2A and 3). DNMT1 forms three
isoforms, which were found in somatic cells, pachytene
spermatocytes, oocytes and preimplantation embryos.
These transcript isoforms are produced by alternative
usage of multiple first exon of DNMT1 primary tran-
script [73]. DNMT3A and DNMT3B enzymes are re-
sponsible for establishment of new methylation pattern
in genomic DNA (Fig. 2B) [15, 27, 121].
Mammalian DNMT1, DNMT3A and DNMT3B are
composed of the N-terminal regulatory and the C-terminal
catalytic domains that are linked by a short fragment of
repeated GK dipeptides (Fig. 4). The N-terminal domains
of DNMT1 and DNMT3B do not exhibit extensive homo-
logy of primary structure. These differences are respon-
sible for distinct functions of N-regions in these enzymes.
The DNMT1 requires interaction between the N- and
C-terminal domains for catalytic activity. Separated C-ter-
minal domain of DNMT1 is catalytically inactive despite
the presence of the highly conserved sequence motifs
Fig. 2. Maintenance (A) and de novo DNMTs (B) methylate DNA.
DNMT1 binds methyl groups to the hemimethylated DNA during
replication, whereas DNMT3A and DNMT3B can add methyl
groups to CpG dinucleotides of unmethylated DNA.
Fig. 3. Methylation of cytosine within CpG dinucleotides is cata-
lyzed by DNMTs. S-adenosylmethionine (SAM) donates methyl
groups and is converted to S- adenosylhomocysteine (SAH).
Fig. 4. Members of mammalian DNMTs family. DNMT1, DNMT3A and DNMT3B consist of N-terminal regulatory and C-terminal catalytic
domains that are linked by repeated GK dipeptides. The N-terminal domain possesses nuclear localization signal sequence (NLS) responsible
for localization of DNMTs in the nucleus. The N-fragment of DNMTs also contains proliferating cell nuclear antigen binding domain (PDB), a
cysteine rich zinc finger DNA binding motif (ATRX), and polybromo homology domain (PHD) targeting DNMTs to the replication foci. However,
PWWP tetrapeptide is only present in N-terminal domains of DNMT3A and DNMT3B and interact with histones [48]. The C-terminal domain
contains six conservative motifs I, IV, VI, VIII, IX and X. Motifs I and X form S-adenosylomethionine binding site, motif IV binds cytosine at the
active site, motif VI possesses glutamyl residue donating protons, and motif IX maintains the structure of the target recognition domain (TRD)
usually located between motifs VIII and IX, that makes base-specific contacts in the major groove of DNA [14, 91, 122, 123].
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typical of active DNMTs. In contrast to DNMT1, C-ter-
minal domain of DNMT3A and DNMT3B is active
without interaction with their N-regulatory regions.
These differences between DNMT1 and de novo
DNMTs indicate significantly disparate mechanism that
regulate methylation activity of these enzymes.
The presence of m5CpG dinucleotides in DNA se-
quence directly inhibits transcription or recruits proteins that
specifically recognize methylated DNA and initiate the re-
modeling of euchromatin into heterochromatin structure.
DNA hypermethylation inhibits gene
transcription 
Two mechanisms have been proposed to account for tran-
scriptional repression via DNA methylation. In the first
mechanism, DNA methylation directly inhibits the binding
of transcription factors (TFs) such as AP-2, c-Myc/Myn,
E2F and NFkB to their binding sites within promoter
sequence. In this mechanism, CpG dinucleotides have to
be present within the binding site of TFs, which are sensi-
tive to methylation of CpG dinucleotides (Fig. 5).
The second mode of repression includes a binding of
proteins specific for m5CpG dinucleotides to methylated
DNA. Methylated DNA recruits m5CpG-binding
(MeCP) and m5CpG-binding domain (MBD) proteins.
MeCP1 and MeCP2 bind specifically to methylated DNA
in whole genome and form spatial obstacle that unable
binding of TFs to promoter sequences (Fig. 5). MeCP1
represses transcription of specific genes, which are control-
led by densely methylated promoters containing more than
ten m5CpG dinucleotides. MeCP2 can bind to a single
symmetrically located m5CpG pair in two DNA strands [44].
MBD protein family includes MBD1, MBD2, MBD3
MBD4, and uncharacterized Kaiso complex, which binds to
methylated DNA. MBD1 binds to symmetrically methy-
lated CpG dinucleotides and inhibits gene expression by
blocking TFs interaction with the promoter [33]. MBD2 may
bind to methylated DNA and actively demethylates DNA in
vivo and in vitro [81, 111]. MBD3 is targeted to methy-
lated DNA through association with the MBD2 and is a
component of the chromatin remodeling protein com-
plex [9]. MBD4 is thymine and uracil glycosylase in-
volved in DNA mismatch repair, formed during C and
m5C deamination, respectively [34, 45]. MBD1, MBD2,
MeCP2, and Kaiso complex are able to interact with
HDAC1 and HDAC2, which deacetylate histones and
remodel chromatin structure [12, 15, 27, 67, 92]. 
Malignant cells also exhibit the hypomethylation of
various regions in DNA that is responsible for increase
in expression of genes promoting proliferation, inva-
sions and metastases of cancer cells.
Role of DNA hypomethylation in cancer
development
Global hypomethylation of genomic DNA is observed in
numerous tumor cells and is responsible for overexpress-
ion of protooncogenes, growth factors and genes which via
their protein products are involved in cancer cell prolifera-
tion, invasion, and metastasis [111]. Expression of tumor
genes such as urokinase type plasminogen activator
(PLAU), heparanase and calcium binding protein
(S100A4) is induced by DNA hypomethylation. Protein
products of these genes promote movement of single
malignant cells through the extracellular matrix to lym-
phatic or blood capillaries. Advanced stage tumors pro-
duce proteases that are involved in degradation of the
extracellular matrix components and promote metastasis
of malignant cells. Heparanases are released from ma-
lignant cells and degrade heparan sulfate proteoglycans
of the extracellular matrix. S100A4 protein regulates
production of matrix-degrading enzymes responsible for
remodeling of the extracellular matrix and increase in
tumor cell proliferation and motility [102].
The most common protease involved in malignant
cell metastasis and invasiveness is the PLAU enzyme.
This protease is expressed in cancers of breast, prostate
and other organs [83, 85]. The expression of PLAU in
invasive human breast cancer MDA-231 cells is con-
Fig. 5. Repression of transcription via CpG dinucleotide methylation.
Promoter sequence binds transctiption factors (TFs) and RNA polymer-
ase II (POL II) that initiates transcription (A). Methylation of CpG within
promoter binding site directly inhibits requirement of TFs and represses
transcription (B). Methylated DNA binds m5CpG binding (MeCPs)
and m5CpG-binding domain (MBDs) proteins forming spatial ob-
stacle that prevents binding of TFs to promoter sequence.
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stitutive, since promoter of this protease gene is un-
methylated [84]. Szyf et al. [111] treated breast cancer
MDA-231 cells with S-adenosylmethionine, a donor of
methyl group and activator of DNMTs (Fig. 2). The
activated DNMTs increased DNA methylation that in-
hibited prometastatic gene expression and reduced inva-
siveness of MDA-231 cells in mouse model. PLAU
promoter is methylated in breast cancer MCF-7 cells and
in noninvasive breast tumor cells. The treatment of
breast cancer MCF-7 cells with the DNMT inhibitors
resulted in production of PLAU protease and increase in
invasiveness of MCF-7 cells in mouse model [111].
Insulin-like growth factor 2 (IGF2) is a growth factor
that stimulates malignant cell proliferation [104]. In
nonmalignant cells, IGF2 is transcribed only from one
allele, while the second one is imprinted and transcrip-
tionally inactive. Hypomethylation of DNA in tumor
genome results in a loss of imprinting of the second allele
and increased biallelic expression of IGF2 that efficient-
ly stimulates proliferation of cancer cells [74, 120].
Hypomethylation of retrotransposons also contributes to
carcinogenesis via destabilization of the genome by inser-
tional mutagenesis and recombination between non-allelic
repeats. Long interspersed nuclear elements (LINEs) belong
to retrotransposons, which are heavily methylated in all cell
types in mammals. Hypomethylation of LINEs induces
transcriptional activation of these sequences, which con-
tributes to genomic instability and facilitates tumor progres-
sion. The methylation of CpG dinucleotides in LINEs and
other retrotransposon sequences is host defense against
retrotransposon activation [14]. Moreover, most cellular
genes contain multiple retrotransposons within introns,
where their transcriptional activation may interfere with
regulation of host gene expression. Hypomethylation of
LINEs has been observed in colon cancer and chronic
lymphocytic leukemia and contributed to the development
of malignant phenotype of these cells [18].
The exact reasons for global DNA hypomethylation in
malignant cells are still unclear. It has been suggested that it
can result from complete or partial deficiency of numerous
enzymes involved in methyl transport at the cellular level
[107]. However, this hypothesis does not explain the simul-
taneous hypermethylation of TSGs promoter and hypo-
methylation of other promoter genes. Some findings suggest
that overexpression of catalytic inactive variants of
DNMT3B specific for DNA sequences may shield CpG
dinucleotides from active DNMTs [122].
DNMT3B isoforms contribute 
to hypermethylation and hypomethylation 
of genomic DNA promoting development, 
invasion and metastases of cancer cells
DNMT3B gene is composed of 23 exons, 22 introns and
is located on 20q11.2. The enzyme is abundantly ex-
pressed in embryonic stem (ES) cells, but DNMT3B ex-
pression is decreased upon differentiation of ES cells and
remains low in adult somatic tissues. However, overex-
pression of various DNMT3B splice variants (Fig. 6) has
been reported in tumor cells suggesting that this enzyme is
responsible for epigenetic modification of DNA [13].
Primary transcript of DNMT3B can be spliced into
five different mRNA isoforms DNMT3B1, DNMT3B2,
DNMT3B3, DNMT3B4 and DNMT3B5 (Fig. 6).
DNMT3B1 and DNMT3B2 contain all the highly con-
served motifs I, IV, VI, IX and X as well as target
recognition domain (TRD) sequence in the C-terminal
domain (Figures 4 and 6). DNMT3B2, DNMT3B3,
DNMTB4 and DNMT3B5 isoforms do not contain
exons 10 and 11 in the mRNA sequences. Moreover,
DNMT3B3, DNMT3B4 and DNMT3B5 lack 21-22, 21
or 22 exons, respectively (Fig. 6). Huntriss et al. [50]
and Weisenberger et al. [122] demonstrated that tran-
script for DNMT3B1 mRNA was only present in ES
cells but was absent from differentiated somatic cells.
This suggests that different DNMT3B isoforms are
predominantly expressed in human somatic as well as
malignant cells. DNMT3B2 variant contains all con-
served motifs of the active site and is abundantly
expressed in breast cancer cell line MCF-7. However,
the effect of depletion of polypeptide fragment corre-
sponding to exons 10 and 11 on function of this
DNMT3B variant is not fully understood [122].
DNMT3B3 lacks the conserved motif VIII, TRD se-
quence and the nine amino acids of motif IX (Figures
4 and 6). However, the expression of DNMT3B3 vari-
ant in LD419 fibroblasts and T24 bladder cancer cells
suggests that human DNMT3B3 possesses catalytic ac-
tivity and can methylate DNA. DNMT3B4 and
DNMT3B5 lack exons that correspond to several con-
servative motifs within the catalytic domain and these
isoforms probably are not enzymatically functional
[122]. Recently, it has been reported that DNMT3B4
functions as a negative regulator of DNA methylation
in human hepatocellular carcinoma (HCC) cells [56 ,
97, 122]. DNMT3B4 can bind to DNA sequences and
compete with the enzymatically active DNMT3B3
variant for targeting to pericentromeric satellite re-
gions of HCC cells. Overexpression of DNMT3B4 in
HCC cells induces DNA demethylation in pericen-
tromeric satellite regions and plays a critical role in
the chromosomal instability and aberrant expression
of cancer-related genes [97].
Depletion of DNMT1 and DNMT3B but not
DNMT3A reactivates the expression of methylation-
silenced genes and induces apoptosis of human cancer
cells but not nonmalignant cells [13, 115]. This may
suggest that methylation silencing of TSGs in numerous
types of cancer is mainly catalysed by DNMT1 and
DNMT3B [7, 90, 93, 97].
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Methylation of tumor suppressor gene
promoters in cancer 
DNA hypermethylation is responsible for epigenetic
inactivation of TSGs expression in cancer cells. Increase
in mRNA and protein biosynthesis of DNMT1 and
DNMT3B in various cancer types significantly corre-
lates with hypermethylation of CpG islands located in
the promoter regions of cyclin-dependent kinase inhibi-
tor 2A (CDKN2A), cyclin-dependent kinase inhibitor 2B
(CDKN2B), E-cadherin (CDH1), human mismatch re-
pair gene (MLH1), retinoblastoma 1 (RB1), TIMP me-
tallopeptidase inhibitor 3 (TIMP3) and other TSGs (Table
1). Methylation of these TSG promoters is associated with
the complete loss of TSG protein products in cancer cells
and development of malignant phenotype [75].
Rhee et al. [89] reported that DNMT1 and DNMT3B
cooperated in order to silence CDKN2A and TIMP3 gene
expression in human colon cancer HCT116 cells. Replace-
ment of conservative motifs in the C-terminal domain of
DNMT1 and DNMT3B by neomycin or hygromycin re-
sistance genes was used to produce double knockout cells
with inactive DNMTs. This resulted in greater than 95%
reduction of genomic DNA methylation and reexpression
of TIMP3 and CDKN2A, which was associated with
growth suppression of HCT116 cells.
Etoh et al. [31] showed in gastric cancer cells signi-
ficantly reduced expression of the CDKN2A, MLH1, and
cell-cell adhesion protein encoded by CDH1 gene. Loss
of expression of mRNAs and proteins of TSGs corre-
lated with intracellular elevation of DNMT1 content and
complete methylation of the CDKN2A, MLH1 and
CDH1 promoters in gastric cancer cells. Similar rela-
tionship between DNMT1 and DNMT3B expression
and CDH1 promoter methylation was observed by Gir-
laut et al. [40] in breast carcinoma. Increased expression
of DNMT1 and DNMT3B were also correlated with the
increase in breast cancer aggressiveness [40]. The epi-
genetic inactivation of CDKN2A and MLH1 genes ex-
pression was also associated with increased level of
DNMT1 and DNMT3B contents in colon cancer cells [55].
Overexpression of DNMT1 and DNMT3B were also
found in ovarian cancer cell lines HeyA8, HeyC2, SK-
OV-3 and PA-1 [3]. HeyA8 and HeyC2 cells exhibited
higher expression of DNMT1 while SK-OV-3 and PA-1
cells overproduced DNMT3B compared to normal
ovarian epithelial cells [3].
Agoston et al. [2] revealed increase in DNMT1 protein
stability in breast cancer MCF-7 cells compared to normal
human mammary epithelial cells (HMECs). It has been
observed that protein levels of DNMT1 are elevated in
breast cancer MCF-7 cells without increase in DNMT1
mRNA level. Elevation of DNMT1 protein level in MCF-7
cells was dependent on the absence of the N-terminal,
120-amino acid fragment which was responsible for longer
half-life of this enzyme. The 120-amino acid sequence
functions as a domain for ubiquitination and proteasome
degradation of DNMT1 in HMECs. The lack of N-termi-
nal domain in DNMT1 may result from improper post-
translational modifications of this enzyme in MCF-7
Fig. 6. Human primary DNMT3B
transcript is spliced into five different
isoforms: DNMT3B1, DNMT3B2,
DNMT3B3, DNMT3B4 and
DNMT3B5. DNMT3B1 and
DNMT3B2 contain all the highly
conserved motifs I, IV, VI, IX and X
as well as TRD sequence in the C-ter-
minal domain (Fig. 4). DNMT3B2,
DNMT3B3 DNMTB4 and
DNMT3B5 isoforms do not contain
exons 10 and 11 in the mRNA se-
quences. Moreover, DNMT3B3,
DNMT3B4 and DNMT3B5 lack
exons 21-22, 21 or 22, respectively.
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cells. The longevity of DNMT1 can be responsible for
elevation of this enzyme activity and increase in methy-
lation of DNA sequences corresponding to promoter of
TSGs [2]. Increase in DNMT1 protein stability was also
observed in prostate cancer cell line LNCaP and colon
cancer cell line HCT116 compared to normal prostate
epithelial cells and normal human dermal fibroblasts [2].
Acute myelogenous leukemia (AML) cells tend to
express higher levels of DNMT1 and DNMT3B. Fur-
thermore, AML cells are characterized by intense
methylation of CDKN2A, CDKN2B, estrogen receptor 1
(ESR1), and RB1 promoters [72].
DNMT3B expression is pronounced in cells of bladder,
colon, kidney and pancreas cancers [91]. A significant corre-
lation between DNMT3B expression and cancer grade was
observed in endometrial cancers [53]. Saito et al. [96]
observed high level methylation of CpG dinucleotides
in CDKN2A promoter and significant overexpression of
DNMT3B in hepatocellular carcinomas compared to the
corresponding noncancerous liver tissue.
Selective depletion of DNMT1 with DNMT and
HDAC inhibitors has been shown to induce demethyla-
tion of promoters and reexpression of the silenced TSGs.
These observations suggest that hypermethylation of
TSGs promoter can be reversed - which may be a target
for possible therapy.
DNA methylation and acetylation-targeted
drugs in cancer therapy
The reversibility of epigenetic changes can be a target
of therapy in cancer [27]. Drugs that epigenetically
influence chromatin structure are divided into DNMT
and HDAC inhibitors. DNMT inhibitors include 5-Aza-
cytidine (5-Aza-CR), 5-Aza-2’-deoxycytidine (5-Aza-
CdR) and 1-β-D-ribofuranosyl-2(1H)-pyrimidinone
(Zebularine) [22, 67, 125]. 5-Aza-CR and 5-Aza-CdR
were first synthesised by Sörm et al. in 1964. These
drugs in vitro profoundly diminish the activity of
DNMT1, DNMT3A and DNMT3B at micromolar con-
centrations and induce demethylation of CDKN2A, RB1,
MLH1 and other TSG promoters in cancer cells [92,
125]. The use of DNMT inhibitors such as 5-Aza-CR
and 5-Aza-CdR can correct silent gene expression pat-
terns and revert cells back to more normal functions.
5-Aza-CR is phosphorylated by uridine-cytidine nucle-
otide kinases to 5-Aza-CR diphosphate which can be
reduced by ribonucleotide reductase to 5-Aza-CdR di-
phosphate and subsequently incorporated into DNA.
5-Aza-CdR is phosphorylated by deoxycytidine, mono-
and diphosphate nucleoside kinases and then incorpor-
ated into DNA. 5-Aza-CdR nucleotide of DNA forms a
covalent bond with the DNMTs and inactivates these
enzymes resulting in inhibition of maintenance and de
novo methylation of genomic DNA (Fig. 7) [74, 92,
111]. Treatment of HCT116 human colon cancer cells
with 5-Aza-CdR depletes DNMT1 enzyme activity, in-
duces expression of MLH1 and causes growth arrest of
these cells [90].
Zebularine was first synthesized by Kim et al. in 1986
[63] as an inhibitor of cytidine deaminase. This substance
is converted to 2’-deoxyZebularine 3-phosphate and then
is incorporated into DNA. 2’-deoxyZebularine nucleotide
of DNA irreversibly inactivates maintenance and de novo
DNMTs by covalently binding to these enzymes (Fig. 7)
[20, 21, 127]. Cheng et al. [22] reported that treatment
of bladder cancer T24 cells with Zebularine induced
CDKN2A gene expression, prevented remethylation of
CDKN2A promoter and arrested growth of the cancer
cells. Zebularine displays two desirable qualities as a
chemotherapeutic agent; this drug is highly stable in acid
and neutral solutions, and exhibits low toxicity in vitro
as well as in vivo in mouse model [28]. These properties
of Zebularine allow continuously treating cancer cells in
vivo in mouse model and prevent remethylation of TSGs
promoter for a long time period [20, 125].
HDAC inhibitors including hydroxamic acid, butyr-
ates, trichostatin A, valproic acid and others (Table 2)
block deacetylation of histones and increase gene ex-
pression. [15, 125]. Primary structure of the active site
of various HDACs is highly conservative and contains
Zn+2 cation [32]. Hydroxamic acid forms complex with
Zn2+ that is essential for function of the active and
binding sites of HDACs. Nanomolar concentrations of
hydroxamic acid inhibit HDACs in vitro and induce
growth arrest and apoptosis of malignant cells [15]. 
The novel useful DNA-demethylating agents are
antisense RNA and short interference RNA (siRNA).
These short RNA fragments are complementary to
mRNA and induce degradation of the target transcripts
[37]. MG98 is an antisense oligonucleotide, which hy-
bridizes to the 3’ untranslated region of the DNMT1
mRNA sequence and causes degradation of this tran-
script [27, 42]. Antisense oligonucleotides and siRNA
directed against DNMT1 mRNA reduced DNMT1 pro-
tein levels. Treatment of thoracic malignancies includ-
ing lung cancer CALU-6, A549 cells and SJGT5, as well
as BIC esophageal adenocarcinoma with antisense oli-
gonucleotides for DNMT1 and DNMT3B resulted in
depletion of these DNMTs. Decrease in DNMTs activity
was associated with RASSF1A and CDKN2A reexpress-
ion and growth arrest of CALU-6, A549, SJGT5 and
BIC cells [58]. siRNA directed to DNMT1 mRNA also
induced demethylation of CDKN2A promoter and ex-
pression of this gene; its protein product inhibited
growth of human colon cancer HCT116 cells [42, 90].
These pieces of evidence have shown that antisense
oligonucleotides and siRNAs are useful as precise anti-
cancer tools activating expression of TSGs and arrest
growth of malignant cells.
Inhibitors of DNMTs and HDACs are currently
tested in clinical trials with patients that suffer from
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cancer [52, 60, 94, 108]. 5-Aza-CR (Vidaza) is the first
DNA hypomethylating agent that was approved by Food
and Drug Administration in 2004, for the treatment of
all subtypes of myelodysplastic syndrome (MDS).
Usage of this drug in cancer therapy exhibits clinical
benefits including elimination of transfusion and com-
plete or partial normalization of blood counts and the
percentage of bone marrow blasts in responding pa-
tients [52]. 5-Aza-CdR (Decitabine) is another DNMT
inhibitor used in the phase I clinical trials in patients
with hematologic malignancies. Decitabine treatment
resulted in myelosuppression in patients that received
low doses of this drug [52]. It has been reported that
treatment of MDS patients with Decitabine results in
partial CDKN2B promoter demethylation in peripheral
leukocytes or bone marrow cells. Currently, Decitabine
Table 1. TSGs promoter and first exon that are commonly methy-
lated in human cancers
TSGs Function
Cancer type
with identified
hyper-
methylation
Refer-
ences
AKAP12 signal transduction gastric  [23]
APC
cell proliferation,
migration and adhesion colorectal  [49]
BRCA1 DNA damage repair breast, ovarian  [30]
CASP8 apoptosis neuroblastoma  [19]
CDH1 cell-cell adhesion
breast,
prostate,
colorectal
[26,
43]
CDKN2A cyclin-dependent kinase
inhibitor
lymphoma  [46]
CDKN2B leukemia  [72]
DAPK1
interferon-induced
apoptosis
lung, B-cell
lymphomas  [59]
GSTP1
prevention of oxidative
DNA damage prostate  [68]
ING1 cell growth and apoptosis lung  [54]
KISS1 chemotaxis and invasion
breast
[106]
LATS2
androgen receptor-
mediated transcription
[112]
MLH1
DNA mismatch repair
gene
colon [117]
PTEN
negatively regulating
AKT/PKB signaling
pathway
colorectal  [41]
RASSF1 cell cycle arrest kidney  [78]
RB1
represses the
transcription of cellular
genes
retinoblastoma [109]
SMAD4 cell proliferation colorectal   [4]
SOCS1 negative regulator of
cytokine signaling
pancreatic  [35]
STK11 signal transduction lung  [98]
TIMP3 inhibitor of the matrix
metalloproteinases
colon, renal,
brain
  [6]
TP53 cell cycle regulator leukemia   [1]
WWOX
transcription regulation,
protein degradation
lung, breast,
bladder  [51]
VHL promotes angiogenesis
renal
carcinoma  [78]
AKT/ PKB - a serine/threonine protein kinase AKT or B
Table 2. DNMT and HDAC inhibitors
Target enzyme Inhibitors References
DNMT1
DNMT3A
DNMT3B
5-Azacytidine  [29]
5-Aza-2’-deoxycytidine  [57]
Hydralazine [101]
MG98 (DNMT1 antisense) [108]
Procainamide [101]
Procaine [119]
siRNA  [69]
Zebularine  [21]
HDACs
Apicidin  [66]
Butyrates [115]
Depudecin  [65]
Hydroxamic acid  [95]
Oxamflatin  [63]
Pyroxamide  [16]
siRNA  [80]
Trichostatin A [116]
Trapoxin A  [61]
Valproic acid  [64]
Fig. 7. Mechanism of DNMT inhibition by nucleoside analogs.
5-Aza-CdR or Zebularine nucleotides are incorporated into DNA
sequences, forming covalent bonds with DNMTs and irreversibly
inactivating these enzymes.
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is successfully applied in the phase II clinical trials [52].
The phase I clinical trial study of the MG98 oligonucleo-
tide revealed that this drug was able to inhibit progression
of solid tumors in patients for a few months [108]. Curren-
tly, MG98 is tested in phase II clinical trials in patients with
mesothelioma, cancer of lung, kidney and colon [108].
Hydroxamic acid and phenylbutyrate are two HDAC
inhibitors which are tested in phase I and II clinical trials,
respectively, in patients with hematological and solid
tumors [60]. The phase I clinical trials indicated that
these HDAC inhibitors could be administered safely to
patients at doses that inhibit HDAC activity in vivo. It
has been also observed that hydroxamic acid and phe-
nylbutyrate treatment results in regression of tumors and
clinical improvement in tumor related symptoms [60].
The best results of transcriptional activation of TSGs
are provided by therapy that uses simultaneously inhibi-
tors of DNMTs and HDACs [39]. The pharmacokinetics
of 5-Aza-CR and phenylbutyrate were preliminary
tested in patients with solid tumors and hematologic
malignancies [94]. These results indicate that the com-
bined strategies of anticancer therapy may ultimately
offer the most successful approach, leading to reduction
in the dose and in side effects of each individual agent
[27]. Additionally, the combined use of DNMT and
HDAC inhibitors makes these drugs more versatile and
results in a synergistic effect on induction of apoptosis,
differentiation, and cycle arrest of various solid tumor
cells [128].
Epigenetic defects in cancer cells is a new area of
carcinogenesis investigation. We presume that epi-
genetic cancer diagnostics and therapy will open new
perspectives in the next decade
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